Zhilin Hou

Zhilin Hou

Auto-generated profile, based on publicly available information

Zhilin Hou

Michigan State University, Department of Chemistry, 578 S. Shaw Ln, East Lansing, MI 48824, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2021 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
DZDi Zhang
Di Zhang
ZHZhilin Hou
Zhilin Hou
KAKelly E. Aldrich
Kelly E. Aldrich
LLLizbeth Lockwood
Lizbeth Lockwood
AOAaron L. Odom
Aaron L. Odom
KLKaren T. Liby
Karen T. Liby
The nuclear factor erythroid-2-related factor 2 (Nrf2)–Keap1–ARE pathway, a master regulator of oxidative stress, has emerged as a promising target for cancer therapy. Mutations in NFE2L2, KEAP1, and related genes have been found in many human cancers, especially lung cancer. These mutations lead to constitutive activation of the Nrf2 pathway, which promotes proliferation of cancer cells and their resistance to chemotherapies. Small molecules that inhibit the Nrf2 pathway are needed to arrest tumor growth and overcome chemoresistance in Nrf2-addicted cancers. Here, we identified a novel small molecule, MSU38225, which can suppress Nrf2 pathway activity. MSU38225 downregulates Nrf2 transcriptional activity and decreases the expression of Nrf2 downstream targets, including NQO1, GCLC, GCLM, AKR1C2, and UGT1A6. MSU38225 strikingly decreases the protein level of Nrf2, which can be blocked by the proteasome inhibitor MG132. Ubiquitination of Nrf2 is enhanced following treatment with MSU38225. By inhibiting production of antioxidants, MSU38225 increases the level of reactive oxygen species (ROS) when cells are stimulated with tert-butyl hydroperoxide (tBHP). MSU38225 also inhibits the growth of human lung cancer cells in both two-dimensional cell culture and soft agar. Cancer cells addicted to Nrf2 are more susceptible to MSU38225 for suppression of cell proliferation. MSU38225 also sensitizes human lung cancer cells to chemotherapies both in vitro and in vivo. Our results suggest that MSU38225 is a novel Nrf2 pathway inhibitor that could potentially serve as an adjuvant therapy to enhance the response to chemotherapies in patients with lung cancer.

16 November 2022 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
ZHZhilin Hou
Zhilin Hou
LLLizbeth Lockwood
Lizbeth Lockwood
DZDi Zhang
Di Zhang
COChristopher John Occhiuto
Christopher John Occhiuto
LMLinqing Mo
Linqing Mo
AOAaron L. Odom
Aaron L. Odom
SAR on NRF2 inhibitor MSU38225 has led to a compound that inhibits expression of NRF2 target genes, reduces proliferation of lung cancer cells through G2/M arrest, and lowers cell migration.

23 December 2022 in Dalton Transactions
Verified
Journal Article
Closed access
PDF file
ZHZhilin Hou
Zhilin Hou
AVAllison S. Vanecek
Allison S. Vanecek
JTJetze Tepe
Jetze Tepe
AOAaron L. Odom
Aaron L. Odom
A rare example of a structurally characterized metal quinoline complex was prepared using a non-covalent quinoline-based proteasome inhibitor (Quin1), and a related complex bearing an inactive quinoline ligand (Quin2) was also synthesized. The quinolines are prepared by a one-pot procedure involving titanium-catalyzed alkyne iminoamination and are bound to ruthenium by reaction with CpRu(NCMe)3 + PF6 − in CH2Cl2. The arene of the quinoline is η6-bonded to the ruthenium metal center. The kinetics of quinoline displacement were investigated, and reactivity with deuterated solvents follows the order acetonitrile > DMSO > water. Quinolines with more methyl groups on the arene are more kinetically stable, and RuCp(Quin1)+ PF6 − (1), which has two methyl groups on the arene, is stable for days in DMSO. In contrast, a very similar complex (2) made with Quin2 having no methyl groups on the arene was readily displaced by DMSO. Both 1 and 2 are stable in 9 : 1 water/DMSO for days with no measurable displacement of the quinoline. The cytotoxicity of the quinolines, their CpRu+-complexes, and CpRu(DMSO)3 + PF6 − was investigated towards two multiple myeloma cell lines: MC/CAR and RPMI 8226. To determine whether the activity of the complexes was related to the nature of the quinoline ligands, two structurally similar quinoline ligands with vastly different biological properties were investigated. Quin1 is a cytotoxic proteasome inhibitor, whereas Quin2 is not a proteasome inhibitor and showed no discernable cytotoxicity. The ruthenium complexes showed poor cellular proteasome inhibition. However, both 1 and 2 showed good cytotoxicity towards RPMI 8226 and MC/CAR, with 1 being slightly more cytotoxic. For example, 1 has a CC50 = 2 μM in RPMI 8226, and 2 has a CC50 = 5 μM for the same cell line. In contrast, CpRu(DMSO)3 + PF6 − was quite active towards MC/CAR with CC50 = 2.8 μM but showed no discernible cytotoxicity toward RPMI 8226. The mechanism of action responsible for the observed cytotoxicity is not known, but the new Ru(Cp)(Quin)+ PF6 − complexes do not cross-link DNA as found for platinum-based drugs. It is concluded that the Ru(Cp)(Quin)+ PF6 − complexes remain intact in the cellular assays and constitute a new class of cytotoxic metal complexes.

3 April 2023
Verified
Other
Open access
DZDi Zhang
Di Zhang
ZHZhilin Hou
Zhilin Hou
KAKelly E. Aldrich
Kelly E. Aldrich
LLLizbeth Lockwood
Lizbeth Lockwood
AOAaron L. Odom
Aaron L. Odom
KLKaren T. Liby
Karen T. Liby
Suppl Fig. 1 lists the primer sequences for NFE2L2 and downstream gene targets of Nrf2. Suppl Fig. 2 shows that MSU38225 does not alter the overall expression pattern of abundant cellular proteins. Suppl Fig. 3 shows that MSU38225 does not inhibit the proliferation of MCF10A cells at concentrations that inhibit the Nrf2 pathway.

3 April 2023
Verified
Other
Open access
DZDi Zhang
Di Zhang
ZHZhilin Hou
Zhilin Hou
KAKelly E. Aldrich
Kelly E. Aldrich
LLLizbeth Lockwood
Lizbeth Lockwood
AOAaron L. Odom
Aaron L. Odom
KLKaren T. Liby
Karen T. Liby
The nuclear factor erythroid-2-related factor 2 (Nrf2)–Keap1–ARE pathway, a master regulator of oxidative stress, has emerged as a promising target for cancer therapy. Mutations in NFE2L2, KEAP1, and related genes have been found in many human cancers, especially lung cancer. These mutations lead to constitutive activation of the Nrf2 pathway, which promotes proliferation of cancer cells and their resistance to chemotherapies. Small molecules that inhibit the Nrf2 pathway are needed to arrest tumor growth and overcome chemoresistance in Nrf2-addicted cancers. Here, we identified a novel small molecule, MSU38225, which can suppress Nrf2 pathway activity. MSU38225 downregulates Nrf2 transcriptional activity and decreases the expression of Nrf2 downstream targets, including NQO1, GCLC, GCLM, AKR1C2, and UGT1A6. MSU38225 strikingly decreases the protein level of Nrf2, which can be blocked by the proteasome inhibitor MG132. Ubiquitination of Nrf2 is enhanced following treatment with MSU38225. By inhibiting production of antioxidants, MSU38225 increases the level of reactive oxygen species (ROS) when cells are stimulated with tert-butyl hydroperoxide (tBHP). MSU38225 also inhibits the growth of human lung cancer cells in both two-dimensional cell culture and soft agar. Cancer cells addicted to Nrf2 are more susceptible to MSU38225 for suppression of cell proliferation. MSU38225 also sensitizes human lung cancer cells to chemotherapies both in vitro and in vivo. Our results suggest that MSU38225 is a novel Nrf2 pathway inhibitor that could potentially serve as an adjuvant therapy to enhance the response to chemotherapies in patients with lung cancer.

3 April 2023
Verified
Other
Open access
DZDi Zhang
Di Zhang
ZHZhilin Hou
Zhilin Hou
KAKelly E. Aldrich
Kelly E. Aldrich
LLLizbeth Lockwood
Lizbeth Lockwood
AOAaron L. Odom
Aaron L. Odom
KLKaren T. Liby
Karen T. Liby
Suppl Fig. 1 lists the primer sequences for NFE2L2 and downstream gene targets of Nrf2. Suppl Fig. 2 shows that MSU38225 does not alter the overall expression pattern of abundant cellular proteins. Suppl Fig. 3 shows that MSU38225 does not inhibit the proliferation of MCF10A cells at concentrations that inhibit the Nrf2 pathway.